Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. With platform-based discovery capabilities, we generate novel peptides to disrupt protein:protein interactions with a focus on disruption of oncogenic transcription complexes, signaling pathways and immune-modulatory mechanisms. We have an emerging pipeline of drug candidates targeting important oncogenic proteins, such as C/EBPβ, β-catenin, and cJun, which have opportunities to address solid tumors and hematologic malignancies, including breast cancer, melanoma, GBM, lung cancer and AML.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
ST101 (C/EBPβ antagonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):